elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q26775573-46DF2362-2056-4F2E-AC94-B1958A1C5C4E
Q26775573-46DF2362-2056-4F2E-AC94-B1958A1C5C4E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26775573-46DF2362-2056-4F2E-AC94-B1958A1C5C4E
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
P2860
Q26775573-46DF2362-2056-4F2E-AC94-B1958A1C5C4E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26775573-46DF2362-2056-4F2E-AC94-B1958A1C5C4E
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b69175530a4fc2432282980614e850f0a7553bc4
P2860
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.